The role of degradant profiling in active pharmaceutical ingredients and drug products

被引:198
作者
Alsante, Karen M.
Ando, Akemi
Brown, Roland
Ensing, Janice
Hatajik, Todd D.
Kong, Wei
Tsuda, Yoshiko
机构
[1] Pfizer Global Res & Dev, Analyt Res & Dev, Groton, CT 06340 USA
[2] Pfizer Global Res & Dev, Analyt Res & Dev, Nagoya, Aichi, Japan
[3] Pfizer Global Res & Dev, Analyt Res & Dev, Sandwich CT13 9NJ, Kent, England
[4] Pfizer Global Res & Dev, Analyt Res & Dev, Chesterfield, MO 63017 USA
关键词
forced degradation; oxidation; acid/base hydrolysis; thermal; humidity; stability-indicating; CAMEO;
D O I
10.1016/j.addr.2006.10.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Forced degradation studies are used to facilitate the development of analytical methodology, to gain a better understanding of active pharmaceutical ingredient (API) and drug product (DP) stability, and to provide information about degradation pathways and degradation products. In order to fulfill development and regulatory needs, this publication provides a roadmap for when and how to perform studies, helpful tools in designing rugged scientific studies, and guidance on how to record and communicate results. (c) 2006 Published by Elsevier B.V.
引用
收藏
页码:29 / 37
页数:9
相关论文
共 16 条
[1]  
ABENDROTH RP, 1994, CHROMCONNECTION JUL, P4
[2]  
Alsante K. M., 2001, Handbook of Modern Pharmaceutical Analysis, P85
[3]  
Alsante K.M., 2003, HDB ISOLATION CHARAC, P361
[4]  
Alsante KM, 2002, SCI COMPUTING IN JUN, P30
[5]  
[Anonymous], 1997, FED REG
[6]  
Baertschi SW, 2005, PHARM STRESS TESTING, V153, P181
[7]  
BYM SJ, 1999, SOLID STATE CHEM DRU, P307
[8]  
*FDA, 1987, UNP DOC STAB HUM DRU
[9]  
FDA, 2018, MICR DAT SYST ANT DR
[10]  
*FDA, 2003, FED REGISTER, V68, P27567